UBS analyst Eliana Merle raised the firm’s price target on BridgeBio (BBIO) to $72 from $65 and keeps a Buy rating on the shares. BridgeBio’s Q1 beat highlights the strong launch start of Attruby, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $50 from $46 at BofA
- Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
- BridgeBio price target raised to $63 from $46 at Piper Sandler
- BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50
- BridgeBio Pharma Reports Q1 2025 Earnings and Pipeline Progress